Amifampridine enhances neuromuscular transmission and relieves muscle weakness, showing promise for Lambert-Eaton myasthenic syndrome and other neuromuscular junction disorders.
Summer 2024
The Summer 2024 online-only issue of NeurologyLive is led by guest editor-in-chief Mary Ann Picone, MD, FAAN, FACP, the medical director of the MS Center at Holy Name Medical Center in Teaneck, New Jersey. It features articles on emerging MRI, OCT, CSF, and blood biomarkers for multiple sclerosis (MS); perspectives on self-managing MS via general consensus, insights from the MS-Selfie project, and a technology-based model; and a NeuroPathways examination of amifampridine in the treatment of Lambert-Eaton myasthenic syndrome and other neuromuscular junction disorders.
Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, explored 3 perspectives on self-managing multiple sclerosis (MS): a general consensus, insights from MS-Selfie, and a future technology-based model.
This article reviews emerging MRI, OCT, CSF, and blood biomarkers, highlighting their potential roles in improving MS patient management and prognosis.
Mary Ann Picone, MD, FAAN, FACP, provides a summary of her time at the recently held 2024 CMSC Annual Meeting.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Orexin Agonist Oveporexton for Narcolepsy Type 1
2
FDA Accepts SL1009 Resubmission for PDCD, Sets December PDUFA Date
3
FDA Grants RMAT Designation to Sasineprocel for Parkinson Disease
4
High-Dose N-Acetyl Cysteine Associated With Reduced GFAP Levels in Phase 2 Progressive MS Study
5